ClinicalTrials.gg
CompletedNCT07564726Updated May 8, 2026

Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol

A Phase 3 interventional study of Amlodipine and Ezetimibe/Rosuvastatin in Hypertension and Hypercholesterolemia, sponsored by Celltrion Pharm, Inc.. Completed at 21 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Primary conditionEssential HypertensionRegistry: HypertensionReclassifiedWhy we changed it
Registry
Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Essential Hypertension
Why
  1. The study's title name Essential Hypertension, a narrower term within Hypertension.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Celltrion Pharm, Inc. (part of Celltrion) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 8 months after the study started (first participant enrolled Aug 2022, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing amlodipine in Essential Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Amlodipine · Essential Hypertension.

Enrollment
22nd of 34
163 · median 314
Started
2022
with 2 others
Phase 3
18 of 34
none open now
Registered
32nd of 34
by date
Lead sponsor
1 of 34
Celltrion Pharm, Inc.

Among the 34 studies testing amlodipine in Essential Hypertension, this one is the 22nd largest by enrollment, is one of 3 that started in 2022, is one of 18 in phase 3, and was the 32nd registered.

Essential Hypertension

479 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

1 of the 34 studies testing amlodipine in Essential Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Essential Hypertension studies recruiting now, 16 (36%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing amlodipine in Essential Hypertension, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test whether one pill that combines ezetimibe, rosuvastatin, and amlodipine can safely lower cholesterol and blood pressure in Korean adults with high blood pressure and high cholesterol.

Read the detailed description

Amlodipine is a calcium channel blocker used for the treatment of hypertension. Rosuvastatin is a statin that inhibits HMG-CoA reductase and is widely used for the treatment of hypercholesterolemia. Ezetimibe is a lipid-lowering agent that inhibits intestinal cholesterol absorption and is commonly used in combination with statins.

This multicenter, randomized, double-blind, active-controlled, phase 3 clinical trial evaluates the efficacy and safety of a fixed-dose combination of ezetimibe, rosuvastatin, and amlodipine in Korean adults with essential hypertension and primary hypercholesterolemia. Following a run-in period that includes therapeutic lifestyle modification, participants are randomized in a 1:1:1 ratio to receive ezetimibe/rosuvastatin/amlodipine 10/20/10 mg or amlodipine 10 mg, or ezetimibe/rosuvastatin 10/20 mg for 8 weeks.

A total of 163 participants were enrolled across 21 study sites. Low-density lipoprotein cholesterol (LDL-C) levels and mean sitting systolic blood pressure (MSSBP) are assessed at Weeks 4 and 8. The primary efficacy endpoints are the percent change in LDL-C from baseline at Week 8 and the change in MSSBP from baseline at Week 8. Secondary endpoints include changes in total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, non-HDL-C, and apolipoprotein B (ApoB).

03

Conditions studied

  • Hypertension
  • Hypercholesterolemia

Browse trials for

Keywords

  • low-density lipoprotein cholesterol (LDL-C)
  • mean sitting systolic blood pressure (MSSBP)
  • Amlodipine
  • Rosuvastatin
  • Ezetimibe
  • phase 3
  • multi-center
  • randomized
  • double-blind
  • active-controlled
  • efficacy and safety
  • combination therapy
  • essential hypertension
  • primary hypercholesterolemia
04

In context

Essential Hypertension Reclassified

479 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

This study's enrollment of 163 is above the median of 144 across 406 interventional studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

Celltrion Pharm, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

First submitted after Celltrion Pharm, Inc. became part of Celltrion.

Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Screening Inclusion Criteria:

  • Age 19 years or older at the time of written
  • Diagnosed with essential hypertension and primary hypercholesterolemia, or currently receiving antihypertensive and/or lipid-lowering medication after such diagnosis
  • If receiving antihypertensive and/or lipid-lowering therapy at screening, judged by the investigator to be medically appropriate for discontinuation of prior therapy during the clinical trial period
  • Able and willing to voluntarily sign the written informed consent form after receiving an explanation of the purpose, methods, and expected effects of the study

Randomization Inclusion Criteria:

  • Mean sitting systolic blood pressure (MSSBP) of at least 140 mmHg and less than 180 mmHg, and mean sitting diastolic blood pressure (MSDBP) less than 110 mmHg
  • Completion of at least 4 weeks of therapeutic lifestyle modification before administration of the product
  • After at least 4 weeks of therapeutic lifestyle modification, fasting LDL-C meeting one of the following criteria:
  • Very high-risk group: LDL-C 70 mg/dL or higher in participants with coronary artery disease, atherosclerotic ischemic stroke or , or peripheral arterial disease
  • High-risk group: LDL-C 100 mg/dL or higher in participants with carotid artery disease, abdominal aneurysm, or diabetes mellitus
  • Moderate-risk group: LDL-C 130 mg/dL or higher in participants with 2 or more major risk factors
  • Low-risk group: LDL-C 160 mg/dL or higher in participants with 1 or fewer major risk factors
  • Fasting triglycerides less than 400 mg/dL and LDL-C 250 mg/dL or lower

Exclusion Criteria:

  • MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg at screening or randomization
  • Difference between arms at screening of MSSBP ≥ 20 mmHg and MSDBP ≥ 10 mmHg
  • History of secondary hypertension or medical history suggestive of secondary hypertension, including coarctation of the aorta, hyperaldosteronism, renal artery stenosis, Cushing disease, pheochromocytoma, or polycystic kidney disease, etc.
  • Symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure of 20 mmHg or more or diastolic blood pressure of 10 mmHg or more on standing compared with sitting or supine blood pressure
  • Subjects with secondary dyslipidemia
  • Severe cardiac disease, including congestive heart failure ( class III or IV), arrhythmia, hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, or hemodynamically significant stenosis of the aortic or mitral valve
  • Unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass grafting, or percutaneous coronary intervention within 6 months prior to screening
  • Retinal hemorrhage, including visual impairment, within 6 months prior to screening
  • Chronic inflammatory disease requiring treatment (e.g., rheumatoid arthritis), or wasting disease, disease, or connective tissue disease
  • Endocrine or metabolic disease known to affect serum lipids or lipoproteins, including uncontrolled diabetes mellitus ( > 9%) or uncontrolled thyroid dysfunction (TSH > 1.5 times the )
  • Severe renal or hepatic impairment, defined as or ALT > 3 times the upper limit of normal, or serum creatinine > 1.5 times the upper limit of normal
  • History of myopathy or rhabdomyolysis, or creatine kinase (CK) > 2 times the upper limit of normal
  • Patients who received, before study participation, treatment with medications that may affect lipid levels, including bile acid sequestrants, anti-obesity medications, fibrates, niacin, or systemic therapy; however, participation is permitted if the relevant has been completed.
  • Need for treatment with protocol-prohibited concomitant medications during the study period
  • History of to ezetimibe, rosuvastatin, amlodipine, or related drug classes
  • Patients with gastrointestinal disease or a history of surgery that may affect drug absorption, distribution, metabolism, or excretion, including current active gastritis, gastrointestinal or rectal bleeding, a history of major gastrointestinal surgery, a history of active inflammatory bowel disease within 12 months before screening, or hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
  • History of drug or alcohol abuse
  • Pregnant or breastfeeding participants, or participants unwilling to use appropriate during the study period
  • History of within 5 years before screening, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, thyroid cancer, or carcinoma in situ of other sites, provided that the disease was successfully treated and there has been no recurrence for at least 3 years; enrollment may be considered at the investigator's medical discretion.
  • Use of another investigational product within 4 weeks prior to screening
  • Any other condition or circumstance that, in the investigator's judgment, would make the participant unsuitable for study participation
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    Amlodipine, Ezetimibe/Rosuvastatin

    Drug: Amlodipine · Drug: Ezetimibe/Rosuvastatin

  • Active comparator
    Amlodipine, Ezetimibe/Rosuvastatin placebo

    Drug: Amlodipine · Drug: Ezetimibe/Rosuvastatin Placebo

  • Active comparator
    Amlodipine placebo, Ezetimibe/Rosuvastatin

    Drug: Ezetimibe/Rosuvastatin · Drug: Amlodipine Placebo

Interventions

  • Oral tablet containing amlodipine 10 mg administered for 8 weeks.

  • DrugEzetimibe/Rosuvastatin

    Drug pages: Ezetimibe · Rosuvastatin

    Fixed-dose combination oral tablet containing ezetimibe 10 mg and rosuvastatin 20 mg administered for 8 weeks.

  • DrugEzetimibe/Rosuvastatin Placebo

    Placebo for ezetimibe/rosuvastatin (10mg/20mg)

  • DrugAmlodipine Placebo

    Placebo for amlodipine (10mg)

07

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8 in Treatment Group and Control Group 1

    Percent change from baseline in LDL-C level.

    Time frame: Baseline, Week 8

  2. Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 in Treatment Group and Control Group 2

    Change from baseline in mean sitting systolic blood pressure. Change is calculated as the Week 8 value minus the baseline value.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 4 in the Treatment Group and Control Group 1

    Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 4 in the treatment group and control group 1.

    Time frame: Baseline, Week 4

  2. Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4 in the Treatment Group and Control Group 2

    Change from baseline in mean sitting systolic blood pressure (MSSBP) at Week 4 in the treatment group and control group 2.

    Time frame: Baseline, Week 4

  3. Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Weeks 4 and 8 in the Treatment Group and Control Group 1

    Change from baseline in mean sitting systolic blood pressure (MSSBP) at Weeks 4 and 8 in the treatment group and control group 1.

    Time frame: Baseline, Week 4, Week 8

  4. Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 4 and 8 in the Treatment Group and Control Group 2

    Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Weeks 4 and 8 in the treatment group and control group 2.

    Time frame: Baseline, Week 4, Week 8

  5. Percent Change From Baseline in TC, TG, HDL-C, non-HDL-C, and Apo B at Weeks 4 and 8 in the Treatment Group, Control Group 1 and Control Group 2

    Percent change from baseline in total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (Apo B) at Weeks 4 and 8 in the treatment group, control group 1, and control group 2.

    Time frame: Baseline, Week 4, Week 8

  6. Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Weeks 4 and 8 in the Treatment Group, Control Group 1, and Control Group 2

    Change from baseline in mean sitting diastolic blood pressure (MSDBP) at Weeks 4 and 8 in the treatment group, control group 1, and control group 2.

    Time frame: Baseline, Week 4, Week 8

  7. Proportion of Participants Achieving Target Blood Pressure at Weeks 4 and 8 in the Treatment Group, Control Group 1, and Control Group 2

    Proportion of participants who achieved target blood pressure at Weeks 4 and 8 in the treatment group, control group 1, and control group 2. Target blood pressure is defined as MSSBP/MSDBP \<140/90 mmHg. For participants with high-risk diabetes mellitus, chronic kidney disease with diabetes mellitus or albuminuria, concomitant cardiovascular disease, or high-risk hypertension, target blood pressure is defined as MSSBP/MSDBP \<130/80 mmHg.

    Time frame: Week 4, Week 8

  8. Proportion of Participants Achieving Target Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 4 and 8 in the Treatment Group, Control Group 1, and Control Group 2

    Proportion of participants who achieved target low-density lipoprotein cholesterol (LDL-C) at Weeks 4 and 8 in the treatment group, control group 1, and control group 2. Target LDL-C is defined according to cardiovascular risk category as follows: very high-risk, \<70 mg/dL; high-risk, \<100 mg/dL; moderate-risk, \<130 mg/dL; and low-risk, \<160 mg/dL.

    Time frame: Week 4, Week 8

08

Study locations

21 sites
  • Korea University Ansan Hospital
    Ansan, South Korea
  • Hallym University Sacred Heart Hospital
    Anyang, South Korea
  • Kosin University Gospel Hospital
    Busan, South Korea
  • Pusan National University Hospital
    Busan, South Korea
  • Dankook University Hospital
    Cheonan, South Korea
  • Daegu Catholic University Medical Center
    Daegu, South Korea
  • Keimyung University Dongsan Medical Center
    Daegu, South Korea
  • Yeungnam University Hospital
    Daegu, South Korea
  • Chonnam National University Hospital
    Gwangju, South Korea
  • Gachon University Gil Medical Center
    Incheon, South Korea
  • Jeonbuk National University Hospital
    Jeonju, South Korea
  • Cha University Bundang Medical Center
    Seongnam, South Korea
  • Asan Medical Center
    Seoul, South Korea
  • Kangbuk Samsung Hospital
    Seoul, South Korea
  • Korea University Anam Hospital
    Seoul, South Korea
  • Korea University Guro Hospital
    Seoul, South Korea
  • Nowon Eulji Medical Center, Eulji University
    Seoul, South Korea
  • Severance Hospital
    Seoul, South Korea
  • The Catholic University of Korea Seoul St. Mary's Hospital
    Seoul, South Korea
  • The Catholic University of Korea Uijeongbu St. Mary's Hospital
    Uijeongbu-si, South Korea
  • Uijeongbu Eulji Medical Center, Eulji University
    Uijeongbu-si, South Korea
09

References and documents

Individual participant data

Plan to share: No — This completed study is being registered retrospectively, and no prospective plan for IPD sharing was specified in the original protocol.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Feb 2024, 18 months.

Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's 18 months is above that.

Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 4, 2026
StartActual
Aug 5, 2022
Primary completionActual
Feb 13, 2024
CompletionActual
Feb 13, 2024
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07564726
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Aug 5, 2022
Primary completion
Feb 13, 2024
Completion
Feb 13, 2024
Last update
May 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amlodipine · Ezetimibe · Rosuvastatin

Start the discussion